Anzeige
Erschienen in:
01.06.2014 | Original Article
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors
Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2014
Einloggen, um Zugang zu erhaltenAbstract
Purpose
This study assessed the cardiovascular safety of cabazitaxel, based on thorough evaluation of QT and non-QT variables, and the relationship between pharmacokinetic and pharmacodynamic electrocardiographic (ECG) profiles and the occurrence of Grade ≥3 cardiovascular adverse events.
Methods
Patients with advanced solid tumors were treated with cabazitaxel 25 mg/m2 every 3 weeks. Digital ECG recordings were obtained during Cycle 1 over 24 h after dosing. The primary end point was effect of cabazitaxel on QT interval corrected by the Fridericia formula (QTcF). Secondary end points were additional ECG parameters (QT, PR and QRS intervals, and heart rate), plasma pharmacokinetics of cabazitaxel and overall clinical safety.
Results
The pharmacodynamic (ECG) population included 94 patients. In 63 patients with a full 24-h ECG evaluation, the maximum upper bound of 90 % confidence interval (CI) for mean QTcF change from baseline was 7.46 ms (mean 4.8 ms), occurring at 1 h 30 min post-infusion. The slope of QTcF change from baseline versus cabazitaxel concentration was slightly negative (−0.012 [95 % CI −0.017; −0.008], equivalent to a 1.2 ms decrease per 100 ng/mL increase in cabazitaxel concentration). For non-QT variables, no effect was noted. No Grade ≥3 cardiac adverse events were observed; Grade ≥3 hypotension and lymphocele occurred in two patients and one patient, respectively.
Conclusion
These results suggest that cabazitaxel has no clinically significant cardiovascular adverse effects in patients with advanced solid tumors.